ReviewLasers in medical science2025
Nanoparticles improved pheophorbide-a mediated photodynamic therapy for cancer.
Review in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Reprogramming Photodynamic Therapy with BODIPY Photosensitizers: From Local Phototoxicity Toward Precision Photodynamic Oncology.Molecules (Basel, Switzerland) · 2026Review
- Nanoparticle-based mechanistic and multifunctional strategies for targeted osteosarcoma therapy.Discover nano · 2026Review
- Primary and Hepatogenous Photosensitization in Livestock: A Review of Plant-Derived Phototoxins and Veterinary Implications.Veterinary sciences · 2026Review
- Article
- Nanoplatform-Enhanced Photodynamic Therapy in Head and Neck Squamous Cell Carcinoma: Advances and Future Directions.International dental journal · 2026Review
- The phytochemistry and pharmacological activities ofFrontiers in pharmacology · 2026Review
- State-of-the-art photodynamic therapy for malignant gliomas: innovations in photosensitizers and combined therapeutic approaches.Exploration of targeted anti-tumor therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increased cancer incidence and mortality rates have made researchers continue to explore different types of effective and less toxic cancer therapies. Photodynamic therapy (PDT) is an alternative cancer treatment modality with reduced side effects. It is comprised of three components, a photosensitizer, molecular oxygen and light. Researchers have been exploring third generation photosensitizers that overcome existing photosensitizer limitations such as hydrophobicity, accurate targeting and photosensitivity. Pheophorbide-a is a chlorophyll product currently being explored in a number of in vitro, in vivo and in silico studies as an ideal photosensitizer for breast, prostate, lung, oral squamous cell carcinoma, gastric, osteosarcoma and cervical cancers. These in vitro, in vivo and in silico studies have shown the probable cell death pathways in different cell lines and how advancement in using nanocarriers has improved cancer cell killing effect after pheophorbide-a mediated PDT. The pharmacokinetics have elaborated on the biodistribution and tissue disposition of pheophorbide-a in this review. In summary, we offer our viewpoint on PDT in the context of cancer management, and we believe that this article will shed new light on the role of pheophorbide-a in PDT for cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.